Literature DB >> 34255545

Affordable Care Act and Cancer Survivors' Financial Barriers to Care: Analysis of the National Health Interview Survey, 2009-2018.

Christopher T Su1,2,3, Dolorence Okullo4, Stephanie Hingtgen4, Deborah A Levine1,4, Susan D Goold1,4,5.   

Abstract

PURPOSE: Since Affordable Care Act (ACA) implementation in 2014, studies have demonstrated gains in insurance coverage for cancer survivors < 65 years. We assessed the impact of ACA implementation on financial barriers to care by stratifying survivors at age 65 years, when individuals typically become Medicare-eligible.
METHODS: We used data from respondents with cancer in the 2009-2018 National Health Interview Survey. We identified 21,954 respondents representing approximately 7.4 million survivors, who were then age-stratified at age 65 years. Survey responses regarding financial barriers to medical care and medications were analyzed, and age-stratified multivariable logistic regression modeling was performed, which evaluated the impact of ACA implementation on these measures, adjusted for demographic and socioeconomic variables.
RESULTS: After multivariable logistic regression, ACA implementation was associated with higher adjusted odds of Medicaid insurance (odds ratio [95% CI] 2.02 [1.72 to 2.36]; P < .0001) and lower adjusted odds of no insurance (0.57 [0.48 to 0.68]; P < .0001). Regarding financial barriers, ACA implementation was associated with lower adjusted odds of inability to afford medications (0.68 [0.59 to 0.79]; P < .0001), inability to afford dental care (0.83 [0.73 to 0.94]; P = .004), and delaying care (0.78 [0.69 to 0.89]; P = .002) in the 18-64 years group. Similarly, ACA implementation was associated with lower adjusted odds of secondary outcomes such as delaying refills, skipping doses, and anxiety over medical bills. Similar associations were not seen in the > 65 years group.
CONCLUSION: Survivor-reported measures of financial barriers in cancer survivors age 18-64 years significantly improved following ACA implementation. Similar changes were not seen in the Medicare-eligible cohort, likely because of high Medicare enrollment and few uninsured.

Entities:  

Mesh:

Year:  2021        PMID: 34255545      PMCID: PMC8791823          DOI: 10.1200/OP.21.00095

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  45 in total

1.  Dental Care And Medicare Beneficiaries: Access Gaps, Cost Burdens, And Policy Options.

Authors:  Amber Willink; Cathy Schoen; Karen Davis
Journal:  Health Aff (Millwood)       Date:  2016-12-01       Impact factor: 6.301

2.  The Affordable Care Act's Medicaid Expansion and Impact Along the Cancer-Care Continuum: A Systematic Review.

Authors:  Haley A Moss; Jenny Wu; Samantha J Kaplan; S Yousuf Zafar
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

3.  Impact of the Patient Protection and Affordable Care Act on cost-related medication underuse in nonelderly adult cancer survivors.

Authors:  Justin M Barnes; Kimberly J Johnson; Eric Adjei Boakye; Rosh K V Sethi; Mark A Varvares; Nosayaba Osazuwa-Peters
Journal:  Cancer       Date:  2020-03-18       Impact factor: 6.860

4.  Out-of-Pocket Spending Under the Affordable Care Act for Patients With Cancer.

Authors:  Matthew S Dixon; Ashley L Cole; Stacie B Dusetzina
Journal:  Cancer J       Date:  2017 May/Jun       Impact factor: 3.360

Review 5.  The ACA's Individual Mandate In Retrospect: What Did It Do, And Where Do We Go From Here?

Authors:  Matthew Fiedler
Journal:  Health Aff (Millwood)       Date:  2020-03       Impact factor: 6.301

6.  Coverage, Financial Burden, and the Patient Protection and Affordable Care Act for Patients With Cancer.

Authors:  Joel E Segel; Jeah Jung
Journal:  J Oncol Pract       Date:  2019-10-11       Impact factor: 3.840

7.  Patient Protection and Affordable Care Act Medicaid expansion and gains in health insurance coverage and access among cancer survivors.

Authors:  Sayeh S Nikpay; Margaret G Tebbs; Emily H Castellanos
Journal:  Cancer       Date:  2018-04-16       Impact factor: 6.860

8.  The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.

Authors:  Erlene K Seymour; Julie J Ruterbusch; Aaron N Winn; Julie A George; Jennifer L Beebe-Dimmer; Charles A Schiffer
Journal:  Cancer       Date:  2020-10-29       Impact factor: 6.860

9.  Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.

Authors:  Nathan E Wineinger; Yunyue Zhang; Eric J Topol
Journal:  JAMA Netw Open       Date:  2019-05-03

10.  Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.

Authors:  Xiaoqin Yang; François Laliberté; Guillaume Germain; Monika Raut; Mei Sheng Duh; Shuvayu S Sen; Dominique Lejeune; Kaushal Desai; Philippe Armand
Journal:  Oncologist       Date:  2021-03-15
View more
  3 in total

1.  Financial Toxicity Interventions in Hematologic Malignancies Are Timely and Necessary.

Authors:  Christopher T Su
Journal:  JCO Oncol Pract       Date:  2022-07-08

2.  What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief.

Authors:  Fantine Giap; Fumiko Chino
Journal:  JCO Oncol Pract       Date:  2021-11-30

3.  Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014-2020.

Authors:  Christopher T Su; Christine M Veenstra; Minal R Patel
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.